Explore
Validate
Learn
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [5]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- BAF969 - Provider product page
- Provider
- R&D Systems
- Product name
- Human FGF-19 Biotinylated Antibody
- Antibody type
- Polyclonal
- Description
- Antigen Affinity-purified. Detects human FGF-19 in ELISAs and Western blots. In sandwich immunoassays, less than 0.05% cross-reactivity with recombinant mouse FGF-15 is observed.
- Reactivity
- Human
- Host
- Goat
- Conjugate
- Biotin
- Antigen sequence
O95750- Isotype
- IgG
- Vial size
- 50 ug
- Concentration
- LYOPH
- Storage
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Submitted references Characterization of a FGF19 variant with altered receptor specificity revealed a central role for FGFR1c in the regulation of glucose metabolism.
FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways.
The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance.
High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis.
Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models.
Ge H, Baribault H, Vonderfecht S, Lemon B, Weiszmann J, Gardner J, Lee KJ, Gupte J, Mookherjee P, Wang M, Sheng J, Wu X, Li Y
PloS one 2012;7(3):e33603
PloS one 2012;7(3):e33603
FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways.
Wu AL, Coulter S, Liddle C, Wong A, Eastham-Anderson J, French DM, Peterson AS, Sonoda J
PloS one 2011 Mar 18;6(3):e17868
PloS one 2011 Mar 18;6(3):e17868
The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance.
Schreuder TC, Marsman HA, Lenicek M, van Werven JR, Nederveen AJ, Jansen PL, Schaap FG
American journal of physiology. Gastrointestinal and liver physiology 2010 Mar;298(3):G440-5
American journal of physiology. Gastrointestinal and liver physiology 2010 Mar;298(3):G440-5
High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis.
Schaap FG, van der Gaag NA, Gouma DJ, Jansen PL
Hepatology (Baltimore, Md.) 2009 Apr;49(4):1228-35
Hepatology (Baltimore, Md.) 2009 Apr;49(4):1228-35
Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models.
Desnoyers LR, Pai R, Ferrando RE, Hötzel K, Le T, Ross J, Carano R, D'Souza A, Qing J, Mohtashemi I, Ashkenazi A, French DM
Oncogene 2008 Jan 3;27(1):85-97
Oncogene 2008 Jan 3;27(1):85-97
No comments: Submit comment
No validations: Submit validation data